How is the Pandemic Affecting MI? The Chinese Experience

ST elevation acute myocardial infarction has high mortality and morbidity rates. It is normally treated with primary PCI. The whole system has established very effective protocols to minimize ischemic time from symptom onset to definite treatment in the cath lab. 

Recomendaciones de la ACC con el nuevo coronavirus

This study reports the experience in Hong Kong since January 2020, when all emergency protocols to contain the Covid-19 pandemic were activated.

This required suspending of all non-essential visits and adjusting services both for hospitalized and ambulatory patients. 

Between January 25 and February 10 2020, there were significant changes in assistance time compared against primary PCI in the same period one year earlier. 

The most affected was time between symptom onset and first medical contact. This depends mostly on patients, who will most likely wait at home for fear of catching Covid-19.


Read also Procedural Rescheduling Criteria in the Pandemic Era.


Historically, time from symptom onset to first medical contact is approximately 82 minutes, and it extended to 318 minutes during the pandemic.

We can scarcely understand the direct impact of this pandemic on the population’s health, let alone measure its indirect impact. 

To the extended onset to first contact time, we should add the extra time needed to identify patient epidemiology, contact history, symptoms, etc. 


Read also: ECS Guidelines for COVID-19 Management.


Finally, when primary PCI is indicated, we should also add extra time for safe patient transport, which involves time for all cath lab staff to wear protective gear. 

Original Title: Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on ST-Segment–Elevation Myocardial Infarction Care in Hong Kong, China.

Reference: Chor-Cheung Frankie Tam et al. Circ Cardiovasc Qual Outcomes. 2020;13:e006631.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....